Immunotherapy

Groundbreaking Trial Shows How Immunotherapy "Changes the Outlook" of Some Cancers

A new drug that has cured patients of rectal cancer is bringing global attention to the benefits and potential of immunotherapy. National Cancer Institute-designated cancer centers like the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) are leading the way in studying the immune regulation of malignant disease to develop novel diagnostic, preventive and treatment regimens.

UMGCCC Expands Immunotherapy Offerings with TIL Therapy for Solid Tumors

UMGCCC is among the first centers in the U.S. to offer FDA-approved tumor-infiltrating lymphocyte (TIL) therapy for advanced melanoma. Discover how this personalized immunotherapy harnesses a patient’s own immune cells to attack solid tumors—and how your patients may benefit from this new treatment option.